Search the Newsreel

FORTRESS BIOTECH INC 9.375% Cumulative Redeemable Preferred Stock Series A USD25.00 (FBIOP.US) will release its earnings report after market close on August 12.

FORTRESS BIOTECH INC (FBIOP.US) is scheduled to release its earnings report after the market closes on August 12. This announcement alerts investors and stakeholders to the upcoming financial disclosure for the company's 9.375% Cumulative Redeemable Preferred Stock Series A.

Why Cannara Biotech Inc. stock is sliding today

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Purple Biotech Ltd (PPBT) Earnings Forecast: Future EPS & Revenue Growth Estimates

Fortress Biotech (FBIO) to Release Earnings on Thursday

Fortress Biotech (FBIO) is scheduled to release its Q2 2026 earnings before market open on Thursday, August 13th, with analysts expecting a loss of $0.20 per share on revenue of $18.30 million. The company's previous quarter significantly beat EPS estimates but slightly missed revenue …

Avecho Biotechnology Ltd (ASX: AVE) Share Price Update: Stock Rises as Health Care Index Closes Lower

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Fortress Biotech, Inc. (NASDAQ: FBIO)

Levi & Korsinsky, LLP has launched an investigation into Fortress Biotech, Inc. (NASDAQ: FBIO) regarding potential breaches of fiduciary duties by its officers and directors. Current FBIO shareholders are encouraged to seek additional information or contact Joseph E. Levi, Esq. to learn more about …

ZYBT Stock Whipsaws As Speculative Trading Dominates Tape

Zhengye Biotechnology Holding Limited (ZYBT) stock is experiencing extreme volatility due to speculative trading, with large price swings that disconnect from its underlying fundamentals. Despite manageable debt and significant assets, the company shows negative returns on invested capital, indicating it's destroying value. Traders are …

PDS Biotechnology Corp (PDSB) Stock News Today

Tianjin Capital Signs Connected EPC Deal for Reclaimed Water Projects

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Recommendation of "Moderate Buy" by Analysts

Legend Biotech Corporation (NASDAQ:LEGN) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $55.29. While the company reported a 56.5% year-over-year revenue increase to $305.1 million, it missed EPS estimates with an adjusted loss of $0.03 per …

Purple Biotech (NASDAQ: PPBT) posts Q2 2026 profit on warrant revaluation

Purple Biotech's IM1240 Shows ~8-Fold Longer Half-Life in Preclinical Data

VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-G

VERAXA Biotech (NASDAQ: VRXA) has advanced its VXA-222 bispecific antibody-drug conjugate (bsADC) program into the next development stage after successfully completing the discovery phase with OmniAb Inc. The company will now focus on engineering the final therapeutic candidate and conducting preclinical validation. VERAXA also …

Concord Biotech Q1 FY27 revenue rises 26% to ₹257 crore on API strength

Hangzhou Diagens Biotechnology Announces Unaudited Interim Results for First Half of 2026

MicroTech Medical Sets August Board Meeting to Review 2026 Interim Results and Possible Dividend

Puma Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Puma Biotechnology, Inc. announced its financial results for the second quarter and six months ending June 30, 2026. For the second quarter, the company saw an increase in revenue to USD 56.5 million and net income rose to USD 8.19 million. However, for the …

PUMA BIOTECHNOLOGY, INC. 2026: Revenue $56.5M, EPS $0.16— 10-Q Summary

PUMA BIOTECHNOLOGY, INC. reported strong quarterly results for 2026, with revenue reaching $56.5 million and diluted EPS of $0.16, demonstrating significant year-over-year growth. Revenue growth was driven by increased volume in core product lines and a shift towards e-commerce, while operational improvements helped streamline …

Oncolytics Biotech (ONCY) Expected to Post Quarterly Earnings on Friday

Oncolytics Biotech (ONCY) is scheduled to release its Q2 2026 earnings after market close on Friday, August 14th, with analysts forecasting a loss of $0.0538 per share. The company previously missed consensus estimates, reporting a $0.08-per-share loss. ONCY shares opened at $0.80, and the …

Puma Biotechnology Inc (PBYI) (Q2 2026) Earnings Call Highlights: Debt-Free Status and Raised ...

Puma Biotechnology Inc. (PBYI) reported strong Q2 2026 results, becoming debt-free and raising its full-year revenue and net income guidance. The company saw significant growth in NERLYNX sales and is advancing its alisertib clinical program, planning for new Phase III trials in 2027. Despite …

Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates

Earnings call transcript: Puma Biotechnology tops Q2 2026 estimates as profit returns

Puma Biotechnology (PBYI) exceeded Q2 2026 revenue and earnings estimates, reporting $56.5 million in revenue and $0.16 GAAP EPS, driven by strong NERLYNX sales. The company returned to profitability after a prior quarter loss and raised its full-year 2026 guidance for net product revenue …

Astrotech (NASDAQ: ASTC) posts $11.2M loss, discusses funding options and shelf

Astrotech Corporation reported a net loss of $11.2 million for the nine months ended March 31, 2026, on revenue of $0.8 million. The company's revenue for the quarter ended March 31, 2026, was $343 thousand, down from $534 thousand a year earlier, with gross …

CollPlant Biotechnologies Bolsters Authorized Share Capital and Validates Resale Shares After July Private Placement

Moleculin Biotech (MBRX) stake capped at 4.99% under Intracoastal warrants

A Schedule 13G filing indicates that Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC collectively hold a beneficial ownership of 4.99% in Moleculin Biotech, Inc. (MBRX), amounting to 973,927 shares. This ownership includes shares held directly by Intracoastal and shares issuable upon …

CollPlant Biotechnologies (CLGN) lifts share capital, files new resale opinion

CollPlant Biotechnologies (CLGN) reported that its shareholders approved an increase in authorized share capital from 30 million to 500 million ordinary shares, each with a par value of NIS 1.50. Following this approval, the company filed an updated legal opinion concerning the validity of …

Concord Biotech Limited Just Beat Revenue Estimates By 5.0%

Moleculin Biotech, Inc. (MBRX) CFO buys 293,333 shares and 879,999 warrants

Moleculin Biotech, Inc.'s CFO, Jonathan P. Foster, recently purchased 293,333 shares of common stock and 879,999 Series I Warrants in a public offering. These were acquired at a combined price of $0.75 per unit, with each unit comprising one share and three warrants. Following …

California State Teachers Retirement System Has $6.76 Million Holdings in Krystal Biotech, Inc. $KRYS

The California State Teachers Retirement System increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 27.2% in the first quarter, now holding 26,186 shares valued at $6.76 million. Krystal Biotech reported strong Q1 earnings per share of $1.79, beating analyst estimates, although revenue slightly …

Moleculin Biotech, Inc. (MBRX) CEO adds stock and 1.6M Series I warrants

Moleculin Biotech, Inc.'s CEO, Walter V. Klemp, reported acquiring 533,333 shares of common stock and 1,599,999 Series I warrants in a public offering on August 3, 2026. The purchase was made at a combined price of $0.75 per common share and three accompanying warrants. …

Is Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) Cheap As ADC Pipeline News Builds?

Vir Biotechnology (VIR) Could Be 58% Below Fair Value On Q2 Profit Turnaround

Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirement

Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) announced that it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. This comes after its Class A ordinary shares closed at or above $1.00 for 10 consecutive business days from July 20 to …

ZYBT Stock Whipsaws As Speculative Trading Frenzy Unwinds

Zhengye Biotechnology Holding Limited (ZYBT) stock experienced extreme volatility, whipsawing significantly due to speculative trading. After a massive 1,047% surge, the stock plunged by over 70% and continued to show significant premarket swings, indicating a classic boom-and-bust pattern driven by momentum rather than fundamentals. …

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Vir Biotechnology reported its second-quarter 2026 financial results, highlighting strong progress in its clinical programs for chronic hepatitis delta (CHD) and solid tumors. Key updates include promising Phase 2 SOLSTICE data for elebsiran and tobevibart in CHD, with Phase 3 ECLIPSE 1 trial data …